Conyers advises Hony Capital Fund V and New Good Management on privatisation of Simcere
Conyers Dill & Pearman has advised Hony Capital Fund V and New Good Management on the $495m (£300m) privatisation of Simcere Pharmaceutical Group from the New York Stock Exchange (NYSE) by way of merger.
Simcere is a pharmaceutical company specialising in the development, manufacture and marketing of branded and proprietary pharmaceuticals in China.
Conyers co-chair David Lamb and associate Angie Chu, both based in Conyers’ Hong Kong office, acted in this matter. They worked alongside Cleary Gottlieb Steen & Hamilton and Shearman & Sterling.
News from Conyers Dill & Pearman
Briefings from Conyers Dill & Pearman
Modern company, partnership, trust, and other related laws have made Bermuda a leading offshore financial centre for the formation of private equity vehicles.
FATCA imposes due diligence, information reporting and control burdens on a range of non-US financial intermediaries and investment entities.